3LBA Everolimus Added to Exemestane Reduced Bone Markers and Disease Progression in Bone in Postmenopausal Women with Advanced Breast Cancer: Updated Results From the BOLERO-2 Trial
Titel:
3LBA Everolimus Added to Exemestane Reduced Bone Markers and Disease Progression in Bone in Postmenopausal Women with Advanced Breast Cancer: Updated Results From the BOLERO-2 Trial
Auteur:
Gnant, M. Hortobagyi, G.N. Rugo, H. Burris, H.A. Noguchi, S. Pritchard, K.I. Baselga, J. Sahmoud, T. Bauly, H. Piccart, M.